Post-Marketing Surveillance of Hepatitis A Virus Vaccine (Avaxim® 160U) in South Korea from 2011 to 2015

被引：0
|
作者：
HeeSoo Kim
Yongho Oh
Yael Thollot
Catherine Bravo
机构：
[1] Sanofi Pasteur,
[2] Sanofi Pasteur,undefined
来源：
Infectious Diseases and Therapy | 2019年 / 8卷
关键词：
Avaxim; Hepatitis A; Safety; Tolerability; Vaccination;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：105 / 112
页数：7
相关论文
共 47 条
  • [21] Allergic adverse events following immunization: Data from post-marketing surveillance in Apulia region (South of Italy)
    Stefanizzi, Pasquale
    Ferorelli, Davide
    Scazzi, Francesco Livio
    Di Lorenzo, Antonio
    Martinelli, Andrea
    Trinchera, Chiara
    Moscara, Lorenza
    Miniello, Enrico
    Di Bona, Danilo
    Tafuri, Silvio
    [J]. FRONTIERS IN IMMUNOLOGY, 2023, 14
  • [22] Post-Marketing Surveillance of Human Rabies Diploid Cell Vaccine (Imovax) in the Vaccine Adverse Event Reporting System (VAERS) in the United States, 1990. 2015
    Moro, Pedro L.
    Woo, Emily Jane
    Paul, Wendy
    Lewis, Paige
    Petersen, Brett W.
    Cano, Maria
    [J]. PLOS NEGLECTED TROPICAL DISEASES, 2016, 10 (07):
  • [23] A post-marketing surveillance study* has revealed no new evidence to suggest that the new measles mumps and rubella virus (MMR) vaccine [Priorix]
    [J]. Reactions Weekly, 2007, 1150 (1) : 3 - 3
  • [24] Safety and Effectiveness of Etanercept Biosimilar SB4 for Rheumatic Diseases in South Korea: Real-World Post-marketing Surveillance Data
    Yoo, Wan-Hee
    Kang, Young Mo
    Kim, Dong Wook
    Kang, Eun Ha
    Lee, Yeon-Ah
    Suh, Chang-Hee
    Sung, Yoon-Kyoung
    Lee, Sang-Hoon
    Gu, Dong-Ha
    Lee, Jiwon
    Choe, Jung-Yoon
    [J]. RHEUMATOLOGY AND THERAPY, 2023, 10 (02) : 329 - 341
  • [25] Safety and Effectiveness of Etanercept Biosimilar SB4 for Rheumatic Diseases in South Korea: Real-World Post-marketing Surveillance Data
    Wan-Hee Yoo
    Young Mo Kang
    Dong Wook Kim
    Eun Ha Kang
    Yeon-Ah Lee
    Chang-Hee Suh
    Yoon-Kyoung Sung
    Sang-Hoon Lee
    Dong-Ha Gu
    Jiwon Lee
    Jung-Yoon Choe
    [J]. Rheumatology and Therapy, 2023, 10 : 329 - 341
  • [26] Adverse events following immunisation with a meningococcal serogroup B vaccine: report from post-marketing surveillance, Germany, 2013 to 2016
    Mentzer, Dirk
    Oberle, Doris
    Keller-Stanislawski, Brigitte
    [J]. EUROSURVEILLANCE, 2018, 23 (17): : 17 - 29
  • [27] A post-marketing surveillance study of a human live-virus pandemic influenza A (H1N1) vaccine (Nasovac®) in India
    Kulkarni, Prasad S.
    Raut, Sidram K.
    Dhere, Rajeev M.
    [J]. HUMAN VACCINES & IMMUNOTHERAPEUTICS, 2013, 9 (01) : 122 - 124
  • [28] Post-Marketing Safety Surveillance of a Childhood Pentavalent Diphtheria-Tetanus-Acellular Pertussis- Polio and Haemophilus influenzae Type B (DTaP-IPV// Hib) Vaccine in South Korea
    Yang, Kuhyun
    Kim, Hyunjung
    Ortiz, Esteban
    Huoi, Catherine
    Kang, Jinhan
    [J]. INFECTIOUS DISEASES AND THERAPY, 2023, 12 (02) : 499 - 511
  • [29] Booster immunization of low- and non-responders after a standard three dose hepatitis B vaccine schedule - Results of a post-marketing surveillance
    Clemens, R
    Sanger, R
    Kruppenbacher, J
    Hobel, W
    Stanbury, W
    Bock, HL
    Jilg, W
    [J]. VACCINE, 1997, 15 (04) : 349 - 352
  • [30] Results from a large post-marketing safety surveillance study in the Republic of Korea with a quadrivalent meningococcal CRM-conjugate vaccine in individuals aged 2 months-55 years
    Yoo, Byung Wook
    Jung, Hye Lim
    Byeon, Yoon Seob
    Han, Dong Ki
    Jeong, Nak Yeong
    Curina, Carlo
    Moraschini, Luca
    Kim, Sung Jin
    Bhusal, Chiranjiwi
    Pellegrini, Michele
    Miao, Yan
    [J]. HUMAN VACCINES & IMMUNOTHERAPEUTICS, 2020, 16 (06) : 1260 - 1267
12345